ACELRX PHARMACEUTICALS INC. overview

AcelRx Pharmaceuticals Announces Publication of Study Evaluating Anticoagulation Practices for Continuous Renal Replacement Therapy in the United States PR Newswire SAN MATEO, Calif., Dec. 12, 2023 Use of CRRT increased during COVID and remained at these higher utilization levels Study results demonstrate challenges physicians have with heparin and citrate, the two currently available CRRT anticoagulants SAN MATEO, Calif. , Dec. 12, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:...

AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate Update PR Newswire SAN MATEO, Calif., Nov. 8, 2023 Niyad™ Investigational Device Exemption (IDE) approval by the FDA achieved in third quarter Company plans to begin its Niyad registrational study this quarter with topline data expected mid-2024 Cash and investments of $13.4 million as of September 30, 2023 Financing closed in July led by new healthcare investors providing up to $26.3 million , of which $10 million was...

AcelRx to Host KOL Panel Discussion on Current Anticoagulant Use in Dialysis and the Upcoming Niyad™ Clinical Study PR Newswire SAN MATEO, Calif., Nov. 7, 2023 Two KOLs will discuss recent quantitative market research on the use of anticoagulants in the dialysis circuit Discussion will also focus on the Niyad study protocol for upcoming NEPHRO Study Register to attend the webcast event on December 6, 2023 at 11:00 a.m. ET SAN MATEO, Calif. , Nov. 7, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals,...

AcelRx to Host Third Quarter 2023 Financial Results Call and Webcast on November 8, 2023 PR Newswire HAYWARD, Calif., Oct. 26, 2023 HAYWARD, Calif. , Oct. 26, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release third quarter 2023 financial results after market close on Wednesday, November...

AcelRx Receives IDE Approval for Niyad and Advances to a Single Registration Study PR Newswire SAN MATEO, Calif., Oct. 3, 2023 Investigational Device Exemption (IDE) approval by the U.S. Food and Drug Administration (FDA) allows AcelRx to begin pivotal study of Niyad™ Single registration study with pre-agreed upon endpoints planned to initiate in Q4 2023 with topline data expected mid-2024; clinical site readiness is currently underway Niyad would be the first and only approved regional...

AcelRx Pharmaceuticals to Participate in the H.C. Wainwright Annual Investment Conference PR Newswire SAN MATEO, Calif., Sept. 6, 2023 SAN MATEO, Calif. , Sept. 6, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that Chief Executive Officer, Vince Angotti will present in-person and be available for...

AcelRx Reports Second Quarter 2023 Financial Results and Provides Corporate Update PR Newswire SAN MATEO, Calif., Aug. 10, 2023 Capital raise closed in July, led by new healthcare investors; provides access to up to $26.3 million in capital, with $10 million immediately available AcelRx awaits response to Emergency Use Authorization (EUA) of Niyad™ submitted to the FDA in April; registrational study set to initiate in Q4 2023 Proforma $17 .4 million in cash as of June 30, 2023, including gross...

AcelRx to Host Second Quarter 2023 Financial Results Call and Webcast on August 10, 2023 PR Newswire HAYWARD, Calif., July 27, 2023 HAYWARD, Calif. , July 27, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release second quarter 2023 financial results after market close on Thursday, August...